Risk of adverse effects of the concomitant use of statins with calcium channel blockers: a systematic review and meta-analysis
Open Access
- 25 June 2026
- journal article
- review article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (6) , 1-16
Abstract
Calcium channel blockers (CCBs) and statins are commonly combined to prevent cardiovascular diseases (CVDs). However, their concomitant use may lead to drug-drug interactions (DDIs) and increased adverse effects (AEs). This systematic review and meta-analysis aimed to evaluate the evidence of adverse effects (AEs) associated with the calcium channel blockers (CCBs) and statins concomitant use. We searched MEDLINE, Embase, Web of Science, and CENTRAL from database inception to 4 April 2025. Eligible studies included randomized controlled trials (RCTs) and observational studies reporting AEs of CCB-statin combinations compared with CCB or statin treatment in adults. Outcomes assessed included CCBs- and statins-associated AEs, treatment discontinuation, hospitalization, and all-cause mortality. Meta-analyses of similar outcomes were performed to estimate pooled Odds Ratios (OR) with 95% confidence intervals (CI). Of 9,737 articles screened, 20 studies (n = 1,053,198) were included. Peripheral edema, myalgia, and discontinuation were most reported in 11, 7, and 9 studies, respectively. Meta-analyses demonstrated no significant differences in the risk of peripheral edema (OR 1.03, 95% CI 0.14-1.48), myalgia (OR 1.33, 95% CI 0.63-2.79), or discontinuation (OR 0.78, 95% CI 0.50-1.23 for CCB-statin vs. CCB; OR 0.97, 95% CI 0.68-1.38 for CCB-statin vs. statin). However, evidence of other AEs was inconsistent and limited. CCB-statin combination appears generally safe in a short-term use (3 to 6 months). Further research is warranted to clarify the long-term risk of AEs.Keywords
This publication has 50 references indexed in Scilit:
- Prevalence, Associated Risk Factors, and Adverse Cardiovascular Outcomes of Statins Discontinuation: A Systematic ReviewPharmacoepidemiology and Drug Safety, 2024
- The impact of correction methods on rare‐event meta‐analysisResearch Synthesis Methods, 2023
- Hypertension and Dyslipidemia Combined Therapeutic ApproachesHigh Blood Pressure & Cardiovascular Prevention, 2022
- Drug-Related Orthostatic Hypotension: Beyond Anti-Hypertensive MedicationsDrugs & Aging, 2020
- Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with HypercholesterolemiaHigh Blood Pressure & Cardiovascular Prevention, 2017
- Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement NetworkPharmacoepidemiology and Drug Safety, 2012
- Reduction in Blood Pressure With StatinsResults From the UCSD Statin Study, a Randomized TrialArchives of internal medicine (1960), 2008
- Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare eventsStatistics in Medicine, 2006
- Effects of Acid and Lactone Forms of Eight HMG-CoA Reductase Inhibitors on CYP-Mediated Metabolism and MDR1-Mediated TransportPharmaceutical Research, 2006
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986